WO2003015507A1 - Development of transgenic model for interventions in neurodegenerative diseases - Google Patents
Development of transgenic model for interventions in neurodegenerative diseases Download PDFInfo
- Publication number
- WO2003015507A1 WO2003015507A1 PCT/US2001/026095 US0126095W WO03015507A1 WO 2003015507 A1 WO2003015507 A1 WO 2003015507A1 US 0126095 W US0126095 W US 0126095W WO 03015507 A1 WO03015507 A1 WO 03015507A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- synuclein
- transgenic
- happ
- mice
- mouse
- Prior art date
Links
- 208000015122 neurodegenerative disease Diseases 0.000 title claims abstract description 16
- 230000004770 neurodegeneration Effects 0.000 title claims abstract description 14
- 238000011161 development Methods 0.000 title claims description 22
- 238000012301 transgenic model Methods 0.000 title description 3
- 101000823051 Homo sapiens Amyloid-beta precursor protein Proteins 0.000 claims abstract description 98
- 238000011830 transgenic mouse model Methods 0.000 claims abstract description 71
- 208000009829 Lewy Body Disease Diseases 0.000 claims abstract description 33
- 201000002832 Lewy body dementia Diseases 0.000 claims abstract description 32
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 10
- 108090000185 alpha-Synuclein Proteins 0.000 claims description 56
- 102000003802 alpha-Synuclein Human genes 0.000 claims description 54
- 108090000623 proteins and genes Proteins 0.000 claims description 43
- 230000014509 gene expression Effects 0.000 claims description 41
- 102000004169 proteins and genes Human genes 0.000 claims description 36
- 230000009261 transgenic effect Effects 0.000 claims description 28
- 230000006735 deficit Effects 0.000 claims description 27
- 230000035772 mutation Effects 0.000 claims description 27
- 101150052863 THY1 gene Proteins 0.000 claims description 14
- 150000001413 amino acids Chemical class 0.000 claims description 8
- 230000008859 change Effects 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 5
- 108700024394 Exon Proteins 0.000 claims description 4
- 230000003619 fibrillary effect Effects 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 3
- 230000016273 neuron death Effects 0.000 claims description 3
- 208000012902 Nervous system disease Diseases 0.000 claims description 2
- 208000025966 Neurological disease Diseases 0.000 claims description 2
- 102000029797 Prion Human genes 0.000 claims description 2
- 108091000054 Prion Proteins 0.000 claims description 2
- 239000002299 complementary DNA Substances 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims 9
- 125000003729 nucleotide group Chemical group 0.000 claims 9
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 5
- 108091026890 Coding region Proteins 0.000 claims 3
- 235000018102 proteins Nutrition 0.000 claims 3
- 108091092195 Intron Proteins 0.000 claims 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 claims 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 claims 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- 235000004279 alanine Nutrition 0.000 claims 2
- 235000001014 amino acid Nutrition 0.000 claims 2
- 229940024606 amino acid Drugs 0.000 claims 2
- 229960000310 isoleucine Drugs 0.000 claims 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 2
- 239000004474 valine Substances 0.000 claims 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 1
- 239000004473 Threonine Substances 0.000 claims 1
- 229960001230 asparagine Drugs 0.000 claims 1
- 235000009582 asparagine Nutrition 0.000 claims 1
- 229930182817 methionine Natural products 0.000 claims 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract description 60
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 46
- 201000010099 disease Diseases 0.000 abstract description 44
- 208000018737 Parkinson disease Diseases 0.000 abstract description 31
- 210000004558 lewy body Anatomy 0.000 abstract description 22
- 108700019146 Transgenes Proteins 0.000 abstract description 17
- 208000037259 Amyloid Plaque Diseases 0.000 abstract description 12
- 230000001575 pathological effect Effects 0.000 abstract description 7
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 abstract description 4
- 238000003556 assay Methods 0.000 abstract description 4
- 241000699670 Mus sp. Species 0.000 description 139
- 241000699660 Mus musculus Species 0.000 description 42
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 38
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 38
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 38
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 37
- 210000004556 brain Anatomy 0.000 description 27
- 230000018109 developmental process Effects 0.000 description 20
- 230000035508 accumulation Effects 0.000 description 15
- 238000009825 accumulation Methods 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- 230000001419 dependent effect Effects 0.000 description 13
- 210000002569 neuron Anatomy 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 12
- 108090000182 beta-Synuclein Proteins 0.000 description 12
- 102000003799 beta-Synuclein Human genes 0.000 description 12
- 239000012634 fragment Substances 0.000 description 11
- 230000002018 overexpression Effects 0.000 description 11
- 230000007170 pathology Effects 0.000 description 11
- 102000019355 Synuclein Human genes 0.000 description 9
- 108050006783 Synuclein Proteins 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- 210000000478 neocortex Anatomy 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 8
- 210000002932 cholinergic neuron Anatomy 0.000 description 8
- 230000001537 neural effect Effects 0.000 description 8
- 230000001717 pathogenic effect Effects 0.000 description 8
- 230000002797 proteolythic effect Effects 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 230000003941 amyloidogenesis Effects 0.000 description 7
- 230000003993 interaction Effects 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 6
- 230000013016 learning Effects 0.000 description 6
- 230000015654 memory Effects 0.000 description 6
- 230000003278 mimic effect Effects 0.000 description 6
- 101150037123 APOE gene Proteins 0.000 description 5
- 101100216294 Danio rerio apoeb gene Proteins 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 210000000225 synapse Anatomy 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 108010058699 Choline O-acetyltransferase Proteins 0.000 description 4
- 102100023460 Choline O-acetyltransferase Human genes 0.000 description 4
- 241000283984 Rodentia Species 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- 230000004075 alteration Effects 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 230000007278 cognition impairment Effects 0.000 description 4
- 208000010877 cognitive disease Diseases 0.000 description 4
- 238000009402 cross-breeding Methods 0.000 description 4
- 210000001320 hippocampus Anatomy 0.000 description 4
- 230000007154 intracellular accumulation Effects 0.000 description 4
- 230000002981 neuropathic effect Effects 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 108700028369 Alleles Proteins 0.000 description 3
- 206010012289 Dementia Diseases 0.000 description 3
- 208000027089 Parkinsonian disease Diseases 0.000 description 3
- 206010034010 Parkinsonism Diseases 0.000 description 3
- 102000006382 Ribonucleases Human genes 0.000 description 3
- 108010083644 Ribonucleases Proteins 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 210000004227 basal ganglia Anatomy 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000006999 cognitive decline Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000007850 degeneration Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000010874 in vitro model Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 230000009251 neurologic dysfunction Effects 0.000 description 3
- 208000015015 neurological dysfunction Diseases 0.000 description 3
- 230000006886 spatial memory Effects 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 2
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 2
- 108010048112 Amyloidogenic Proteins Proteins 0.000 description 2
- 102000009091 Amyloidogenic Proteins Human genes 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 201000010374 Down Syndrome Diseases 0.000 description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
- 206010018341 Gliosis Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 108010021466 Mutant Proteins Proteins 0.000 description 2
- 102000008300 Mutant Proteins Human genes 0.000 description 2
- 102000004874 Synaptophysin Human genes 0.000 description 2
- 108090001076 Synaptophysin Proteins 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000003942 amyloidogenic effect Effects 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 230000003466 anti-cipated effect Effects 0.000 description 2
- 208000037875 astrocytosis Diseases 0.000 description 2
- 230000007341 astrogliosis Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000002600 fibrillogenic effect Effects 0.000 description 2
- 102000004963 gamma-Synuclein Human genes 0.000 description 2
- 108090001121 gamma-Synuclein Proteins 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 210000005154 hemibrain Anatomy 0.000 description 2
- 210000003000 inclusion body Anatomy 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 230000000626 neurodegenerative effect Effects 0.000 description 2
- 230000007996 neuronal plasticity Effects 0.000 description 2
- 230000007171 neuropathology Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 238000012261 overproduction Methods 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 231100000255 pathogenic effect Toxicity 0.000 description 2
- 230000007505 plaque formation Effects 0.000 description 2
- 210000000063 presynaptic terminal Anatomy 0.000 description 2
- 210000002637 putamen Anatomy 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 102200036626 rs104893877 Human genes 0.000 description 2
- 102200036620 rs104893878 Human genes 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 210000003523 substantia nigra Anatomy 0.000 description 2
- 230000007470 synaptic degeneration Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000031836 visual learning Effects 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 102100029470 Apolipoprotein E Human genes 0.000 description 1
- 101710095339 Apolipoprotein E Proteins 0.000 description 1
- 102000013918 Apolipoproteins E Human genes 0.000 description 1
- 108010025628 Apolipoproteins E Proteins 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010067889 Dementia with Lewy bodies Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108050001049 Extracellular proteins Proteins 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 208000001089 Multiple system atrophy Diseases 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 102000012412 Presenilin-1 Human genes 0.000 description 1
- 108010036933 Presenilin-1 Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 206010044688 Trisomy 21 Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 230000004849 abnormal protein aggregation Effects 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 210000004727 amygdala Anatomy 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- 230000007131 anti Alzheimer effect Effects 0.000 description 1
- 230000001896 anti-amyloidogenic effect Effects 0.000 description 1
- 230000000648 anti-parkinson Effects 0.000 description 1
- 239000000939 antiparkinson agent Substances 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 238000010256 biochemical assay Methods 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 210000004671 cell-free system Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 210000004720 cerebrum Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 210000000330 cholinergic fiber Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 210000000877 corpus callosum Anatomy 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 208000015756 familial Alzheimer disease Diseases 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229920006158 high molecular weight polymer Polymers 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003585 interneuronal effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 230000002197 limbic effect Effects 0.000 description 1
- 210000003715 limbic system Anatomy 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000001423 neocortical effect Effects 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 210000002241 neurite Anatomy 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000007971 neurological deficit Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000004031 neuronal differentiation Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000011506 response to oxidative stress Effects 0.000 description 1
- 238000010825 rotarod performance test Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000010246 ultrastructural analysis Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
- A01K2267/0312—Animal model for Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
- A01K2267/0318—Animal model for neurodegenerative disease, e.g. non- Alzheimer's
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
Definitions
- This invention relates to transgenic mice for use in the study of neurodegenerative diseases.
- AD Alzheimer's disease
- PD Parkinson's disease
- LBD Lewy Body disease
- AD Alzheimer's disease
- each disease is associated with the degeneration of neurons, interneuronal synaptic connections and eventually cell death, the depletion of neurotransmitters, and abnormal accumulation of misfolded proteins, the precursors of which participate in normal central nervous system function.
- ⁇ -synuclein also known as NACP (Non-amyloid component precursor).
- NACP Non-amyloid component precursor
- NAC Non-amyloid component precursor
- LBD neurodegenerative disorders denominated Lewy body disease
- Patients with LBD are characterized by dementia, parkinsonism, psychiatric alterations, deposition of amyloid, and formation of Lewy bodies (LBs) with filamentous characteristics.
- LBs are the pathogenic hallmark of both PD and LBD.
- the neuritic plaques that are the classic pathological hallmark of AD are composed essentially of A ⁇ , a 39-43 amino acid (aa) proteolytic product of the Alzheimer's amyloid precursor protein (APP), and NAC, a 35 aa proteolytic fragment of the NACP protein. Both A ⁇ and NAC were first identified in amyloid plaques as proteolytic fragments of their full
- mutations are denoted by the wild type amino acid, the number of the amino acid at which the mutation is found and the amino acid that is found in the mutant form of the protein.
- mutations seem to alter the processing of APP preferentially to the A ⁇ 2 proteolytic fragment, which has a propensity to form aggregates that are pathogenic.
- mutations cannot account for the majority of Alzheimer's patients in whom the disease arises spontaneously.
- APP is expressed abundantly in synapses under normal conditions, is well conserved across species, and has been implicated in neural plasticity, learning, and memory.
- APP has three alternative splice variants in which exons 7 and 8 (hAPP695), exon 8 (hAPP751 ) or no exons (hAPP770) are spliced out of the full length transcript.
- the ratio of the three forms varies between regions of the brain and in normal vs. disease states; however, no definitive pattern of normal vs. abnormal has been determined
- proteolytic fragments A ⁇ 39 ⁇ 3 under normal conditions. Disease results from an imbalance in the production of the fragments, biasing the overproduction of the proteolytic fragments,
- ⁇ -Synuclein is part of a large family of proteins including ⁇ - and ⁇ -synuclein and synoretin. As with APP, ⁇ -synuclein is expressed in the normal state in synapses and is
- a ⁇ is secreted from neurons and accumulates in extracellular amyloid plaques. Additionally A ⁇ can be detected inside neurons. ⁇ -Synuclein accumulates in intraneuronal inclusions called Lewy bodies. Although the two proteins are typically found together in extracellular neuritic AD plaques, they are also occasionally found together in intracellular inclusions.
- Aggregates may be formed in nerve cell cultures by overexpression of ⁇ - synuclein. Overexpression of wild-type APP does not cause formation of extracellular protein aggregates in culture; however, overexpression of the Swedish APP mutation, the most pathogenic of the APP mutations, does. Aggregates may also be formed in
- transgenic APP failed to show extensive AD-type neuropathology (Kammesheidt et al., 1992; Lamb et al., 1993; Mucke et al., 1994; Higgins et al., 1995; Andraa et al., 1996). This was likely due to low levels of protein expression. Games et al. (1995) were able to generate a transgenic mouse that showed some AD-type pathology due to the high level of expression of a mutant APP (V717F) driven by a PDGF- ⁇ promoter. The transgenic animals did exhibit deposits of human A ⁇ in the hippocampus, corpus callosum and the cerebral cortex, but in no other regions of the brain. Plaques were observed, but there were no neurofibrilary tangles. The author stated that such results were expected as neurofibrilary tangles did not exist in rodents.
- mice were found to have normal learning and memory at 3 months, but showed impairment by 9 or 10 months. Plaques were observed in the cortical and
- a ⁇ 2 fragment was toxic to the cells, but no plaques were formed, suggesting a plaque independent role for A ⁇ 1-42 in the progression of AD.
- transgenic animals expressing APP were found to display a variety of neurological problems including learning deficits, disturbed behavior and seizures. Again, the severity of neurological dysfunction seemed to be tied to the level of expression of the APP protein. Differences could also be attributed to the regions of the brain in which APP was expressed due to differences in promotors, integration into the genome, etc. As with the physiological symptoms though, neurological dysfunction in these animals resembled some aspects, but not all, of those seen in AD, PD and LBD. The lack of an animal model
- mice in which the mutant gene was expressed were found to be lethal in inbred FVB/N or C57BL/6J mice (Carlson, et al., 1997). Lines of FVB/N mice
- mice expressing ⁇ -synuclein under control of the PDGF ⁇ promotor have also been generated for use as a model of PD and LBD (Masliah et al., 2000). Neuronal expression of ⁇ -synuclein resulted in the progressive accumulation of ⁇ -synuclein and the
- mice demonstrated motor impairments which were associated with loss of dopaminergic terminals in the basal ganglia. However, no amyloid plaques, fibrillary tangles or cell death were observed.
- mice have also been generated.
- promotors e.g. PDGF ⁇ , Thy-1
- both wild type and mutant forms A30P and A53T
- none of the mice provide a completely accurate model of PD.
- differences were seen in the amount and location of protein expressed, depending on the promoter used and the site of insertion of the transgene into the genome. For example, when expression from the h ⁇ -synuclein transgene was driven by the PDGF- ⁇ promotor, the
- mice expressing mutant versions of h ⁇ -synuclein developed hallmarks of disease earlier than those expressing the wild type version of the protein. Additionally, neurological dysfunction was dependent on the regions of the brain in which the protein was expressed.
- the invention is a transgenic mouse model with transgenes for expression of human ⁇ -amyloid peptides or hAPP and h ⁇ -synuclein.
- the transgenes may be wild type, mutant or truncated forms of the genes.
- the transgenes may be expressed under any of a number of promoters including the PDGF- ⁇ , Thy1 and prion (PrP) promoters.
- An intron such as the SV40 intron, may be included in the transgene construct or the promotor, as in the case of the Thy1 promoter, the intron of the promoter may be used.
- the mice of the present invention are generated by crossbreeding of mice carrying
- transgenic mouse lines overexpressing h ⁇ -synuclein (Masliah et al., 2000) and either wild- type or mutant forms of hAPP (Mucke et al, 2000) to elucidate the in vivo mechanism of amyloidogenesis in AD, PD and LBD. Additionally, there are a number of other hAPP transgenic mice available as referenced. Available mice include those expressing APP
- Thy1 promoter under control of the mouse or human Thy1 promoter (Andraa et al, 1996), the PDGF- ⁇ promoter (Games et al., 1995) with orwithout an SV40 intron, and the PrP (Borchelt et al.,
- mice are well studied and characterized regarding regions of the brain and time frame in which the transgenes are expressed.
- transgenes can readily be generated by crossing two mice that overexpress either hAPP or h ⁇ - synuclein in regions of the brain most effected by AD, PD or LBD as desired. Ideally the mice crossed should carry only one copy of the transgene such that littermates expressing both, either or neither transgene can be compared to each other. Overexpression of transgenes can be detected by any of a number of methods well known to one skilled in the art including, but not limited to, ribonuclease protection assay (RPA), Western blot, immunofluorescence, or like analysis, where the signal obtained is above background cross-reactivity with mouse RNA or protein found in non-transgenic littermates.
- RPA ribonuclease protection assay
- the bigenic PDGF- ⁇ - ⁇ -synuclein-PDGF- ⁇ -hAPP mice of the invention have been shown to express high levels of APP which is properly processed into A ⁇ fragments, in addition to exhibiting extracellular amyloidosis and neurofibrilary tangles which, in an age-
- hAPP bigenic mice resembled the Lewy body variant of AD. Bigenic mice developed
- the onset of motor deficits began at 6 months with the bigenic mice, rather than at 12 months as is typically seen with the PDGF- ⁇ -hAPP mice.
- the bigenic mice showed the most prominent age-dependent degeneration of cholinergic neurons and presynaptic terminals as compared to their singly- or non-transgenic littermates. Although synaptic degeneration was observed in the singly transgenic mice, neuronal cell death was not observed in the singly transgenic littermates.
- hAPP- ⁇ -synuclein mice also had abundant ⁇ -amyloid plaques and an even greater number of ⁇ -synuclein-immunoreactive neuronal inclusions.
- the present invention is a method for the evaluation of the in vivo effects of ⁇ -synuclein with APP, in combination, on amyloidogenesis and neurodegeneration. Evaluation of the effects of the proteins in the development and progression of disease may be assessed by functional, pathological or biochemical assays,
- synuclein and hAPP/A ⁇ have distinct, as well as overlapping, pathogenic effects on the integrity and function of the brain. While h ⁇ -synuclein did not affect the A ⁇ -dependent development of neuritic plaques or the overall A ⁇ content in the brain, it worsened hAPP/A ⁇ -dependent cognitive deficits and neurodegeneration in specific brain regions. These findings indicate that h ⁇ -synuclein can enhance the toxicity of A ⁇ through plaque- independent mechanisms. They correlate well with clinical observations suggesting that people with the Lewy body variant of AD have a more rapid cognitive decline than people with pure AD.
- hAPP/A ⁇ Overexpression of hAPP/A ⁇ , in turn, promoted the intraneuronal accumulation of h ⁇ -synuclein in transgenic mice and accelerated the development of motor deficits.
- drugs aimed at blocking the accumulation of A ⁇ or h ⁇ -synuclein will likely benefit a broader spectrum of neurodegenerative disorders than previously anticipated.
- the bigenic mouse provides a better predictive model of the potential for an intervention to be useful to a patient.
- FIGURE 2. RNase protection assay of total RNA from brains of transgenic and non-
- transgenic mice Lane U represents undigested transcripts. The right hand side notation of the figure indicate the size of the digested samples. Sample lanes represent analysis of three separate mice each from Non-Tg, non-transgenic mice (i.e. control); Thy1 -hAPPtg, transgenic mice; Thy 1 - ⁇ -syn'tg , transgenic mice; and double tg, transgenic mice containing both the human (h)APP751 and the ⁇ -synuclein genes.
- mice that express different levels of each protein By using mice that express different levels of each protein, one can obtain a variety of models with different rates of onset and severity of disease. These will mimic the differences seen in
- Transgenic mice expressing hAPP or ⁇ -synuclein can be divided into two general categories of low expressing and high expressing strains. The classes can be further subdivided into mice that express wild type proteins that are less toxic than mutant proteins. For example, all mice expressing APP will eventually develop some plaques and
- mice expressing the Swedish double mutation at aa 670/671 will result in disease with fewer plaques in age matched animals.
- different mutations and promoters will manifest various severity of disease in ⁇ -synuclein transgenic mice.
- Mice expressing h ⁇ -synuclein under the control of a Thy-1 promoter accumulate protein in the synapses and neurons throughout the brain, including the thalmus, basal ganglia, substantia nigra and brainstem.
- mice expressing ⁇ -synuclein under the control of the PDGF- ⁇ promoter accumulate protein in synapses in the neocortex, limbic system and olfactory regions, as well as in inclusion bodies in neurons in deeper layers of the neurocortex.
- Another strain displayed ⁇ -synuclein expression in glial cells mimicking multiple system atrophy.
- mice expressing hAPP and h ⁇ -synuclein in regions of the brain most severely effected in LBD could be crossed to serve as a model for LBD.
- transgenic mice are selected based on criteria including level and brain region of protein expression, age of development of symptoms, neurological disorders and effect of background strain. Unlike transgenic mice that are generated by the insertion of
- mice of the invention are bigenic mice generated by the combination of mice with well known
- Models are designed to most closely fit the disease of interest based on the criteria among those listed above.
- the expression of one protein is not disrupted by the expression of the other.
- the enhancement of the pathology of ⁇ -synuclein by co- expression of hAPP is now known.
- One skilled in the art may make rational decisions in combining known strains of mice to develop bigenic strains that most closely mimic the
- Transgenic mice are achieved routinely in the art using the technique of microinjection, as described in U.S. Patent No. 4,736,866 issued to Leder et al., and as provided by B. Hogan et al. (1986).
- U.S. Patent 5,574,206 issued to Jolicoeur particularly describes the creation of transgenic mice bearing functional HIV genes and their use in the modeling and study of HIV-mediated diseases. These references are herein incorporated by reference.
- h ⁇ -synuclein and hAPP Coexpression of h ⁇ -synuclein and hAPP in vivo.
- Transgenic mice in which neuronal expression of h ⁇ -synuclein (Masliah et al., 2000) or FAD-mutant hAPP (Mucke et al., 2000) is directed by the PDGF ⁇ chain promoter have been described. Additionally, a number of other APP mice have been described including, but not limited to, those described in the present application. Lines with high levels of neuronal h ⁇ -synuclein (line D) or A ⁇ (line J9) production were selected.
- EXAMPLE 3 Overexpression of human ⁇ -synuclein in bigenic mice enhances Alzheimer's disease-like neuropathology. It has been established that both ⁇ -synuclein and NAC are integral components of plaques formed in in vitro models of Alzheimer's disease. In order to determine how these molecules contribute to amyloidogenesis in vivo, specifically in the PDAPP bigenic mouse models, brain sections from effected bigenic mice were treated with formic acid and immunostained with antibodies against ⁇ -synuclein and NAC.
- ⁇ -synuclein is critical for plaque formation in vivo and as such, constitutes a reasonable target for the design of anti-amyloidogenic compounds useful for in vivo therapies of Alzheimer's disease and other neurodegenerative conditions involving amyloid formation.
- EXAMPLE 4 Neurological deficits in h ⁇ -synuclein/hAPP mice. Motor deficits were assessed with the rotarod test (FIG. 1). Consistent with previous observations, h ⁇ -synuclein mice developed age-dependent motor deficits. At 6 months of age, h ⁇ -synuclein/hAPP mice already showed deficits relative to nontransgenic controls (P ⁇ 0.03 by repeated measures ANOVA), whereas h ⁇ -synuclein mice still performed normally. At 12 months of age, both h ⁇ -synuclein and h ⁇ -synuclein/hAPP mice showed deficits in this test compared with nontransgenic controls (P ⁇ 0.001 by repeated measures ANOVA).
- hAPP mice had no significant motor deficits at either age. The severity of motor deficits was similar in 6- month-old h ⁇ -synuclein/hAPP and 12-month-old h ⁇ -synuclein and h ⁇ -synuclein/hAPP mice, suggesting that hAPP/A ⁇ accelerates the development of h ⁇ -synuclein-dependent motor deficits.
- PDGF-hAPP mice have previously been shown to develop cognitive deficits. To determine the effects of h ⁇ -synuclein and hAPP/A ⁇ on spatial learning and memory, mice were assessed in a water maze test (Morris, 1984).
- mice In the sessions during which the target platform was visible, all groups of mice were able to locate the platform equally well, indicating that the motor deficits of h ⁇ -synuclein/hAPP do not preclude normal performance in the water maze test.
- mice In the hidden platform sessions, mice have to use their memory of the spatial relationship of the platform to visual cues outside of the maze to locate the submerged platform.
- h ⁇ -synuclein/hAPP mice showed the most significant learning deficits, whereas h ⁇ -synuclein mice and nontransgenic controls performed normally.
- hAPP mice tended to perform better than h ⁇ -synuclein/hAPP mice in the hidden platform sessions, but the difference was not statistically significant.
- the probe trial during which the platform is removed provides a putative measure of spatial memory retention.
- h ⁇ -synuclein/hAPP mice and hAPP mice showed significantly less preference for the target quadrant than nontransgenic controls, suggesting impaired memory retention, whereas h ⁇ -synuclein mice were not impaired.
- Lewy body diseases which also combine motor and cognitive deficits.
- Synaptophysin-immunoreactive presynaptic terminals of defined signal intensity (SIPT) in the neocortex of 4- to 20-month-old mice (n 15-19/genotype) were measured.
- SIPT defined signal intensity
- SIPT levels in the neocortex were highest in nontransgenic controls (25.6 ⁇ 0.9) and lowest in h ⁇ -synuclein/hAPP mice (18.3 ⁇ 4.8, P ⁇ 0.05 by Tukey-Kramer test), with values for hAPP mice (20.9 ⁇ 1.7) and h ⁇ -synuclein mice (23.0 ⁇ 0.9) falling in between.
- SIPT levels in the caudate/putamen at 20 months of age were normal in nontransgenic mice (27.1 ⁇ 1.5) and hAPP mice (25.1 ⁇ 3.6), but decreased in h ⁇ -synuclein mice (21.0 ⁇ 0.9) and h ⁇ -synuclein/hAPP mice (20.1 ⁇ 1.7) (P ⁇ 0.05 vs nontransgenic controls by Tukey-Kramer test).
- EXAMPLE 6 A ⁇ promotes accumulation of h ⁇ -synuclein. Accumulation of h ⁇ -synuclein within neurons is a hallmark of Lewy body diseases, including the Lewy body variant of AD. Age- dependent accumulation of h ⁇ -synuclein in neurons of h ⁇ -synuclein singly transgenic mice has been previously observed (Masliah, 2000). Between 4 and 20 months of age, the number of neuronal inclusions in the neocortex was on average 1.6-fold higher in h ⁇ - synuclein/hAPP mice than in age-matched h ⁇ -synuclein mice (15.3 ⁇ 1.1 vs.
- a ⁇ , ⁇ and A ⁇ also differed in their effect on the intracellular accumulation of ⁇ -synuclein in neuronal cell cultures when added to the culture medium.
- a ⁇ 2 strongly increased the intracellular accumulation of ⁇ -synuclein, but A ⁇ o did not.
- RNA from hemibrains or from dissected brain regions was isolated and then analyzed by a solution hybridization RNase protection assay and resolved on a acrylamide/urea/Tris/borate/EDTA gel ( Figure 2).
- Lane U represents undigested transcripts of the ⁇ -synuclein gene ( ⁇ -syn), the A ⁇ precursor gene (APP) and actin
- Sample lanes represent analysis of three separate mice each from Non-Tg, non-transgenic mice (i.e. control); Thy1-hAPPtg, transgenic mice expressing human (h)APP751 cDNA under the regulatory control of the murine (m)Thy-1 gene; They1- ⁇ - syn'tg, transgenic mice expressing human ⁇ -synuclein under the regulatory control of the muring (m)Thy-1 gene; and double tg, transgenic mice containing both the human (h)APP751 and the ⁇ -synuclein genes under the regulatory control of the murine
- EXAMPLE 8 Crossbreeding ofha-synuclein or PDAPP-J9M tg mice with ma- or m ⁇ -synuclein KO mice.
- knock out mice having the genes encoding ⁇ -synuclein or ⁇ - synuclein deleted (Lexicon Genetics Inc., The Woodlands, TX) were crossed with heterozygous PDAPP-J9M tg mice.
- ⁇ -synuclein and ⁇ -synuclein on amyloid deposition was evaluated in both the homozygous KO mice (PDAPP+/+;m ⁇ -syn-/-) and in the mice hemizygous for synuclein (PDAPP+/+;m ⁇ -syn+/-) utilizing the same rotorod and neuropathological analysis used in previous examples.
- Lewy body diseases are common neurodegenerative disorders, second only to AD. They comprise a heterogeneous group of diseases including PD, diffuse Lewy body disease, and the Lewy body variant of AD.
- Lewy body disease typically has Lewy bodies, parkinsonism and cognitive impairments. Approximately 25% of patients with AD develop frank parkinsonism, and h ⁇ -synuclein-immunoreactive Lewy body-like inclusions develop in most cases of sporadic AD and FAD, as well as in Down's syndrome, which is associated with early-onset AD. Moreover, Lewy bodies contain hAPP. These associations indicate that hAPP/A ⁇ plays a role in the formation of Lewy bodies and the development of Lewy body diseases.
- h ⁇ -synuclein mice demonstrate that h ⁇ -synuclein and hAPP/Ab have distinct, as well as convergent, pathogenic effects on the integrity and function of the brain. While h ⁇ -synuclein did not affect the A ⁇ -dependent development of neuritic plaques or the overall A ⁇ content in the brain, it worsened hAPP/A ⁇ -dependent cognitive deficits and neurodegeneration in specific brain regions. These findings indicate that h ⁇ -synuclein enhances the toxicity of A ⁇ through plaque- independent mechanisms. These data explain clinical observations suggesting that people with the Lewy body variant of AD have a more rapid cognitive decline than people with pure AD.
- hAPP/A ⁇ Overexpression of hAPP/A ⁇ , in turn, promoted the intraneuronal accumulation of h ⁇ -synuclein in transgenic mice and accelerated the development of motor deficits. These effects were most likely mediated by A ⁇ or another hAPP product, in vitro studies indicate that A ⁇ is the culprit. In view of these pathogenic interactions between A ⁇ and h ⁇ -synuclein, drugs aimed at blocking the accumulation of Ab or h ⁇ -synuclein will benefit a broader spectrum of neurodegenerative disorders than previously anticipated.
- Oxidative stress induces amyloid-like aggregate formation of ⁇ ACP/ ⁇ -synuclein in vitro. Neuroreport 10:717-21.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Environmental Sciences (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Animal Husbandry (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biodiversity & Conservation Biology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- Public Health (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Physics & Mathematics (AREA)
- Diabetes (AREA)
- Plant Pathology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002458193A CA2458193A1 (en) | 2001-08-20 | 2001-08-20 | Development of transgenic model for interventions in neurodegenerative diseases |
JP2003520278A JP2004538013A (en) | 2001-08-20 | 2001-08-20 | Development of genetic recombination model for medical treatment of neurodegenerative diseases |
PCT/US2001/026095 WO2003015507A1 (en) | 2001-08-20 | 2001-08-20 | Development of transgenic model for interventions in neurodegenerative diseases |
EP01964267A EP1420635A1 (en) | 2001-08-20 | 2001-08-20 | Development of transgenic model for interventions in neurodegenerative diseases |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2001/026095 WO2003015507A1 (en) | 2001-08-20 | 2001-08-20 | Development of transgenic model for interventions in neurodegenerative diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003015507A1 true WO2003015507A1 (en) | 2003-02-27 |
Family
ID=21742790
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/026095 WO2003015507A1 (en) | 2001-08-20 | 2001-08-20 | Development of transgenic model for interventions in neurodegenerative diseases |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1420635A1 (en) |
JP (1) | JP2004538013A (en) |
CA (1) | CA2458193A1 (en) |
WO (1) | WO2003015507A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7550649B2 (en) | 2003-10-30 | 2009-06-23 | Taisho Pharmaceutical Co., Ltd. | Transgenic non-human mammal |
US8502016B1 (en) | 2005-02-11 | 2013-08-06 | Elan Pharmaceuticals, Inc. | Genomic alpha synuclein transgenic animal |
US9802992B2 (en) | 2005-12-06 | 2017-10-31 | Tokyo Metropolitan Institute Of Medical Science | Cell into which protein, which can serve as polymerization nucleus of protein polymer, or polymer thereof is introduced, and method for production of the cell |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001060794A2 (en) * | 2000-02-18 | 2001-08-23 | The Regents Of The University Of California | Method for screening for anti-amyloidogenic properties and method for treatment of neurodegenerative disease |
-
2001
- 2001-08-20 WO PCT/US2001/026095 patent/WO2003015507A1/en active Application Filing
- 2001-08-20 EP EP01964267A patent/EP1420635A1/en not_active Withdrawn
- 2001-08-20 JP JP2003520278A patent/JP2004538013A/en not_active Withdrawn
- 2001-08-20 CA CA002458193A patent/CA2458193A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001060794A2 (en) * | 2000-02-18 | 2001-08-23 | The Regents Of The University Of California | Method for screening for anti-amyloidogenic properties and method for treatment of neurodegenerative disease |
Non-Patent Citations (9)
Title |
---|
BORCHELT DAVID R ET AL: "A vector for expressing foreign genes in the brains and hearts of transgenic mice.", GENETIC ANALYSIS BIOMOLECULAR ENGINEERING, vol. 13, no. 6, 1996, pages 159 - 163, XP002201748 * |
GOLDBERG M S ET AL: "Studies of human alpha-synuclein in transgenic mice.", SOCIETY FOR NEUROSCIENCE ABSTRACTS., vol. 25, no. 1-2, 1999, 29th Annual Meeting of the Society for Neuroscience.;Miami Beach, Florida, USA; October 23-28, 1999, pages 2055, XP002943679, ISSN: 0190-5295 * |
IWAI AKIHIKO: "Properties of NACP/alpha-synuclein and its role in Alzheimer's disease.", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1502, no. 1, 2000, pages 95 - 109, XP002201749, ISSN: 0006-3002 * |
KRUEGER R ET AL: "Involvement of alpha-synuclein in Parkinson's disease and other neurodegenerative disorders.", JOURNAL OF NEURAL TRANSMISSION, vol. 107, no. 1, 26 January 2000 (2000-01-26), pages 31 - 40, XP002201751, ISSN: 0300-9564 * |
MASLIAH ELIEZER ET AL: "beta-Amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 98, no. 21, 9 October 2001 (2001-10-09), October 9, 2001, pages 12245 - 12250, XP002201752, ISSN: 0027-8424 * |
MASLIAH ELIEZER ET AL: "Dopaminergic loss and inclusion body formation in alpha-synuclein mice: Implications for neurodegenerative disorders.", SCIENCE (WASHINGTON D C), vol. 287, no. 5456, 18 February 2000 (2000-02-18), pages 1265 - 1269, XP002201745, ISSN: 0036-8075 * |
MUCKE L ET AL: "Potential roles of alpha1-antichymotrypsin and alpha-synuclein in Alzheimer's pathogenesis assessed in bigenic mice expressing human amyloid precursor proteins.", SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 25, no. 1-2, 1999, 29th Annual Meeting of the Society for Neuroscience, Part 1;Miami Beach, Florida, USA; October 23-28, 1999, pages 302, XP002943680, ISSN: 0190-5295 * |
MUCKE LENNART ET AL: "High-level neuronal expression of Abeta1-42 in wild-type human amyloid protein precursor transgenic mice: Synaptotoxicity without plaque formation.", JOURNAL OF NEUROSCIENCE, vol. 20, no. 11, 1 June 2000 (2000-06-01), pages 4050 - 4058, XP002201746, ISSN: 0270-6474 * |
STURCHLER-PIERRAT CHRISTINE ET AL: "Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 94, no. 24, 25 November 1997 (1997-11-25), Nov. 25, 1997, pages 13287 - 13292, XP002201747, ISSN: 0027-8424 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7550649B2 (en) | 2003-10-30 | 2009-06-23 | Taisho Pharmaceutical Co., Ltd. | Transgenic non-human mammal |
US8502016B1 (en) | 2005-02-11 | 2013-08-06 | Elan Pharmaceuticals, Inc. | Genomic alpha synuclein transgenic animal |
US9802992B2 (en) | 2005-12-06 | 2017-10-31 | Tokyo Metropolitan Institute Of Medical Science | Cell into which protein, which can serve as polymerization nucleus of protein polymer, or polymer thereof is introduced, and method for production of the cell |
Also Published As
Publication number | Publication date |
---|---|
CA2458193A1 (en) | 2003-02-27 |
JP2004538013A (en) | 2004-12-24 |
EP1420635A1 (en) | 2004-05-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7393994B2 (en) | Transgenic mouse model for neurodegenerative diseases | |
Wakamatsu et al. | Selective loss of nigral dopamine neurons induced by overexpression of truncated human α-synuclein in mice | |
Moechars et al. | Expression in brain of amyloid precursor protein mutated in the alpha‐secretase site causes disturbed behavior, neuronal degeneration and premature death in transgenic mice. | |
EP0946712B1 (en) | Transgenic animal models with modulated phenotype for alzheimer's disease | |
Lim et al. | FTDP-17 mutations in tau transgenic mice provoke lysosomal abnormalities and Tau filaments in forebrain | |
DE69533583T2 (en) | NOT HUMAN, TRANSGENIC MAMMALS WITH DEVELOPING NEUROLOGICAL DISEASE | |
US7186881B2 (en) | Testing compounds for effects on synaptophysin in transgenic mice expressing an Alzheimer's disease FAD DNA sequence | |
Kumar-Singh et al. | Behavioral disturbances without amyloid deposits in mice overexpressing human amyloid precursor protein with Flemish (A692G) or Dutch (E693Q) mutation | |
US6649811B2 (en) | Transgenic mouse expressing the human cyclooxygenase-2 gene and neuronal cell cultures derived therefrom | |
US20070118915A1 (en) | Transgenic mice comprising a genomic human tau transgene | |
JP2000513929A (en) | Transgenic non-human mammal with progressive neurological disease | |
EP0620849A1 (en) | Transgenic animal models for alzheimer's disease | |
Jakobsen et al. | Expression of the Alzheimer’s disease mutations AβPP695sw and PSEN1M146I in double-transgenic Göttingen minipigs | |
JP2001517065A (en) | Methods for identifying therapeutic agents for Alzheimer's disease using transgenic animal models | |
US6452065B2 (en) | Transgenic mouse expressing non-native wild-type and familial Alzheimer's Disease mutant presenilin 1 protein on native presenilin 1 null background | |
US7479579B2 (en) | Triple transgenic mouse model of Alzheimer's disease | |
JPH11507821A (en) | Methods for identifying therapeutic agents for Alzheimer's disease using transgenic animal models | |
JP4824902B2 (en) | Double transgenic animals with Alzheimer's disease | |
EP1420635A1 (en) | Development of transgenic model for interventions in neurodegenerative diseases | |
DE60118913T2 (en) | Transgenic animal model for neurodegenerative diseases | |
DE60121324T2 (en) | ANIMAL MODEL FOR NEURODEGENERATIVE DISEASES | |
EP2096910A2 (en) | Transgenic mammals modified bri protein expression | |
US20030131364A1 (en) | Method for producing transgenic animal models with modulated phenotype and animals produced therefrom | |
und Halbach | Analysis of animal models of neurodegenerative diseases with protein deposits | |
Vickers | Genetically Engineered Models of Human Age-Related Neurodegenerative Diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ PH PL PT RO SD SE SG SI SK SL TJ TM TR TT TZ UG UZ VN YU ZA |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZW AM AZ BY KG KZ MD TJ TM AT BE CH CY DE DK ES FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003520278 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2458193 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001964267 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2001964267 Country of ref document: EP |